within Pharmacolibrary.Drugs.ATC.V;

model V08CA12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 8.999999999999999e-05,
    k12             = 0.14,
    k21             = 0.14
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadopiclenol is a macrocyclic, nonionic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) for the enhancement of images of the central nervous system, body, and associated structures. It is indicated for use in adults and children to detect and visualize regions with disrupted blood–brain barrier or abnormal vascularity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model in healthy adult volunteers following single intravenous administration.</p><h4>References</h4><ol><li><p>Bradu, A, et al., &amp; Bourrinet, P (2021). Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function. <i>Investigative radiology</i> 56(8) 486–493. DOI:<a href=\"https://doi.org/10.1097/RLI.0000000000000764\">10.1097/RLI.0000000000000764</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34197356/\">https://pubmed.ncbi.nlm.nih.gov/34197356</a></p></li><li><p>Hao, J, et al., &amp; Desché, P (2019). Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). <i>Investigative radiology</i> 54(7) 396–402. DOI:<a href=\"https://doi.org/10.1097/RLI.0000000000000556\">10.1097/RLI.0000000000000556</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30870257/\">https://pubmed.ncbi.nlm.nih.gov/30870257</a></p></li><li><p>Fries, P, et al., &amp; Müller, A (2019). Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength. <i>Investigative radiology</i> 54(9) 549–558. DOI:<a href=\"https://doi.org/10.1097/RLI.0000000000000572\">10.1097/RLI.0000000000000572</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31033675/\">https://pubmed.ncbi.nlm.nih.gov/31033675</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA12;
